Want to see HNGE full AI Analyst Report?
Earnings Data
Report Date
Aug 04, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.61Last Year’s EPS
0.35Same Quarter Last Year
Strong Buy
Based on 15 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: a material revenue beat, double-digit growth in billings, substantial margin expansion, strong free cash flow, raised full-year guidance, rapid client uptake of the new migraine program following FDA clearance, and expanding commercial traction (including SMB and Hinge Select). Headwinds and risks include limited near-term revenue from migraine (meaningful benefit expected in 2027), concentration of new bookings in the back half of the year, continued device-related cost pressures as Enso distribution scales, and a deliberate decision to forgo the CMS ACCESS program. Overall, the positives (robust growth, margin expansion, guidance raise, product and commercial wins) substantially outweigh the near-term lowlights and risks.Company Guidance
Revenue Beat and Strong Top-Line Growth
Q1 revenue of $182M, up 47% year-over-year from $124M, materially above company guidance of $171M–$173M.
Calculated Billings Expansion
Last twelve months calculated billings reached $770M, a 52% increase vs $507M in the prior year period.
Robust Margin and Profitability Improvement
Gross margin improved to 85% (up 400 bps YoY); operating margin was 25% vs 12% in Q1 2025 (improvement of ~1,300 bps); operating income of $46M, above guidance of $30M–$32M.
Free Cash Flow and Balance Sheet Strength
Free cash flow of $42M (10x YoY), free cash flow margin 23% vs 3% prior-year; cash and cash equivalents of $407M at quarter end.
Raised Full-Year Guidance
Full-year 2026 revenue guidance raised to $798M–$804M (midpoint $801M, ~36% YoY growth) and income from operations guidance increased to $205M–$215M (26% margin midpoint), up from prior ranges.
Product Expansion: Migraine Program and FDA Clearance
Launched migraine care program; Enso received 510(k) FDA clearance for migraine. Trial outcomes: 56% saw pain reduction from severe/moderate to mild/none with at least one waveform; 1.9x likelihood to reduce pain vs placebo. >125 clients adopted program in weeks, covering >2M eligible lives.
Commercial Momentum and Network Growth
Pipeline substantially higher vs Q1 2025; SMB pipeline growth >100% YoY; Hinge Select reached 4,100 provider locations and expanded distribution through a national PBM and 3 of the 5 largest national health plans. ~80% of contracted lives are on engagement-based pricing.
Capital Deployment and Share Count Reduction
Executed $105M share repurchase for 2.5M shares in Q1; diluted weighted average shares fell to 82.4M; reported diluted net income per share of $0.45.
HNGE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HNGE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $49.75 | $54.84 | +10.23% |
Feb 10, 2026 | $33.05 | $38.76 | +17.28% |
Nov 04, 2025 | $53.44 | $45.39 | -15.06% |
Aug 05, 2025 | $48.22 | $60.55 | +25.57% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Hinge Health, Inc. Class A (HNGE) report earnings?
Hinge Health, Inc. Class A (HNGE) is schdueled to report earning on Aug 04, 2026, After Close (Confirmed).
What is Hinge Health, Inc. Class A (HNGE) earnings time?
Hinge Health, Inc. Class A (HNGE) earnings time is at Aug 04, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HNGE EPS forecast?
HNGE EPS forecast for the fiscal quarter 2026 (Q2) is 0.61.